MedTrace Logo

Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

NCT06341842 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2024-04-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab. The study aims to describe the efficacy for dapagliflozin as compared to standard of care. Participants will be recruited in participating centers, where they are planning on starting (neo-) adjuvant ACT-based chemotherapy and/or trastuzumab for stage I-III breast cancer.

Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapaglifloziin 10 mg 1 tab daily

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-19
Primary Completion
2025-04-19
Completion
2025-04-19

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06341842 on ClinicalTrials.gov